Delving into the Latest Updates on Shanghai AsiFlyer Biotechnology Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Skin and Musculoskeletal Diseases

Biological products

Toxin

Antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	4

Top 5 Drug Type	Count

Biological products	3
Antibody	1
Toxin	1

Top 5 Target	Count

SNAP25(Synaptosomal-associated protein 25)	1

[Translation] A multicenter, randomized, double-blind, positive-controlled phase II clinical trial evaluating the efficacy, safety, and immunogenicity of injectable recombinant botulinum toxin type A (Sf9 cells, 150 kD natural amino acid sequence) for the treatment of moderate to severe glabellar lines.

主要目的：探索不同剂量的注射用重组A型肉毒毒素（Sf9细胞，150 kD天然氨基酸序列）治疗中、重度眉间纹的有效性。次要目的：探索不同剂量的注射用重组A型肉毒毒素（Sf9细胞，150 kD天然氨基酸序列）治疗中、重度眉间纹的其它有效性、安全性、免疫原性。

[Translation]

Primary objective: To explore the efficacy of different doses of injectable recombinant botulinum toxin type A (Sf9 cells, 150 kD natural amino acid sequence) in the treatment of moderate to severe glabellar lines. Secondary objective: To explore other efficacy, safety, and immunogenicity of different doses of injectable recombinant botulinum toxin type A (Sf9 cells, 150 kD natural amino acid sequence) in the treatment of moderate to severe glabellar lines.

Start Date-

Sponsor / Collaborator

Shanghai AsiFlyer Biotechnology Co., Ltd.

CTR20253490

/ Not yet recruitingPhase 1

评价注射用重组 A 型肉毒毒素（Sf9 细胞，150 kD 天然氨基酸序列）治疗中、重度眉间纹的安全性、耐受性、免疫原性和有效性的随机、双盲、安慰剂、阳性对照的 I 期临床研究

[Translation] A randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the safety, tolerability, immunogenicity, and efficacy of recombinant botulinum toxin type A (Sf9 cells, 150 kD native amino acid sequence) for the treatment of moderate to severe glabellar lines.

主要目的评价注射用重组A型肉毒毒素（Sf9细胞，150 kD天然氨基酸序列）治疗中、重度眉间纹的安全性和耐受性次要目的评价注射用重组A型肉毒毒素（Sf9细胞，150 kD天然氨基酸序列）治疗中、重度眉间纹的免疫原性初步评价注射用重组A型肉毒毒素（Sf9细胞，150 kD天然氨基酸序列）治疗中、重度眉间纹的有效性

[Translation]

Primary Objective: To evaluate the safety and tolerability of recombinant botulinum toxin type A (Sf9 cells, 150 kD natural amino acid sequence) for the treatment of moderate to severe glabellar lines. Secondary Objective: To evaluate the immunogenicity of recombinant botulinum toxin type A (Sf9 cells, 150 kD natural amino acid sequence) for the treatment of moderate to severe glabellar lines. To conduct a preliminary evaluation of the efficacy of recombinant botulinum toxin type A (Sf9 cells, 150 kD natural amino acid sequence) for the treatment of moderate to severe glabellar lines.

Start Date-

Sponsor / Collaborator

Shanghai AsiFlyer Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai AsiFlyer Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai AsiFlyer Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai AsiFlyer Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai AsiFlyer Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

3

Preclinical

Phase 2

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Botulinum Toxin Type A (AsiFlyer) ( SNAP25 )	Upper limb spasticity More	IND Approval
AFB-ZBZ(MD)	Neuromuscular Diseases More	Preclinical
AFB-ZBZ(KD)	Neuromuscular Diseases More	Preclinical
AFB-ZBZ(MG)	Neuromuscular Diseases More	Preclinical